PSTV Plus Therapeutics: שווי החברה בספרים

Plus Therapeutics, Inc. (PSTV) is developing innovative radiotherapy methods to combat solid breast and brain tumors, diversifying its research portfolio to minimize risks. The business relies on scaling nanoliposomal drugs and securing US government grants, remaining independent of economic cycles due to stable demand. The price visualization available on the page confirms this data, with the metric standing at 0.01.

The assessment of business vulnerability to external shocks is based on an analysis of net assets minus all liabilities, allowing the investor to determine the real value of Plus Therapeutics, Inc. (PSTV) without accounting for borrowed capital. The use of government grants in the development of radiopharmaceuticals by Plus Therapeutics, Inc. (PSTV) strengthens this foundation; therefore, the capital dynamics on the balance sheet serve as an indicator of bankruptcy protection and warn against overpaying for the asset.